EUVIMEDEUVIMED entdecken
Open Access

Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis

Holly Wobma iD, Sage R Arvila, Maria L Taylor iD, Ki Pui Lam, Marina Ohashi, Catherine Gebhart, Helene Powers, Siobhan Case, Mia T Chandler iD, Margaret H Chang, Ezra Cohen, Megan Day-Lewis und 15 weitere

Arthritis Care & Research · 2023-10 · 75 (10) · 2063-2072

DOI: 10.1002/acr.25129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 18.05.2023. Verfasst von Holly Wobma und 26 weiteren Autor:innen. Beteiligte Einrichtung: Boston Children's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Lung Diseases, Eosinophilia, Biological Products. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Although interleukin‐1 (IL‐1)/IL‐6 inhibitors are effective therapies for systemic juvenile idiopathic arthritis (JIA), some patients develop eosinophilia and lung disease during treatment. This study was undertaken to retrospectively evaluate incidence and risk factors for eosinophilia and describe lung disease outcomes in IL‐1/IL‐6 inhibitor–exposed patients with systemic JIA.

Methods

Among JIA patients at our institution exposed to interleukin‐1 (IL‐1)/IL‐6 inhibitors (1995–2022), we compared incidence rate of eosinophilia in systemic JIA compared to other JIA, stratified by medication class (IL‐1/IL‐6 inhibitors, other cytokine inhibitors, methotrexate). We used Cox models to identify predictors of eosinophilia during IL‐1/IL‐6 inhibitor use and summarized treatment changes and outcomes after eosinophilia, including lung disease. HLA typing was performed on a clinical or research basis.

Results

There were 264 new medication exposures in 75 patients with systemic JIA and 41 patients with other JIA. A total of 49% of patients with systemic JIA with HLA typing (n = 45) were positive for HLA–DRB1*15 alleles. Eosinophilia was common during IL‐1/IL‐6 inhibitor use and did not differ by systemic JIA compared to other JIA (0.08 and 0.07 per person‐year, respectively; P = 0.30). Among systemic JIA patients, pretreatment macrophage activation syndrome (MAS) was associated with a higher rate of subsequent eosinophilia on biologic therapy (unadjusted hazard ratio 3.2 [95% confidence interval 1.2–8.3]). A total of 4 of 5 patients who switched therapy within 10 weeks of eosinophilia experienced disease flare compared to none of the patients who continued the original therapy. A total of 8 of 25 patients with pulmonary evaluations had lung disease, and all had severe manifestations of systemic JIA (MAS, intensive care unit stay). One death was attributed to systemic JIA–lung disease.

Conclusion

Eosinophilia is common in JIA patients using IL‐1/IL‐6 inhibitors. Severe disease may be associated with eosinophilia and lung disease in systemic JIA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileLung DiseasesEosinophiliaBiological ProductsHumansChildIncidenceRetrospective StudiesInterleukin-6 InhibitorsRisk FactorsInterleukin-1

Substanzen

Interleukin-6 InhibitorsInterleukin-1Biological Products

Autor:innen und Institutionen

  • Boston Children's Hospital, Boston, Massachusetts.
  • HLA-Lab, American Red Cross, Dedham, Massachusetts.
  • Boston Children's Hospital and Brigham & Women's Hospital, Boston, Massachusetts.

ORCID-Profile: Holly Wobma, Maria L Taylor, Mia T Chandler, Pui Y Lee, Mindy S Lo, Fatma Dedeoğlu, Joyce Chang, Lauren A Henderson

Förderung

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Lupus Foundation of America
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Heart and Lung Institute
  • Arthritis National Research Foundation

Zitieren

APA

Wobma, H., Arvila, S. R., Taylor, M. L., Lam, K. P., Ohashi, M., Gebhart, C., Powers, H., Case, S., Chandler, M. T., Chang, M. H., Cohen, E., Day-Lewis, M., Fishman, M. P., Halyabar, O., Hausmann, J. S., Hazen, M. M., Lee, P. Y., Lo, M. S., Meidan, E., …, & Henderson, L. A. (2023). Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care & Research, 75(10), 2063-2072. https://doi.org/10.1002/acr.25129

Vancouver

Wobma H, Arvila SR, Taylor ML, Lam KP, Ohashi M, Gebhart C, et al. Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care & Research. 2023;75(10):2063-2072. doi:10.1002/acr.25129

BibTeX
@article{Wobma2023,
  author = {Wobma, Holly and Arvila, Sage R and Taylor, Maria L and Lam, Ki Pui and Ohashi, Marina and Gebhart, Catherine and Powers, Helene and Case, Siobhan and Chandler, Mia T and Chang, Margaret H and Cohen, Ezra and Day-Lewis, Megan and Fishman, Martha P and Halyabar, Olha and Hausmann, Jonathan S and Hazen, Melissa M and Lee, Pui Y and Lo, Mindy S and Meidan, Esra and Roberts, Jordan E and Son, Mary Beth F and Sundel, Robert P and Dedeoğlu, Fatma and Nigrovic, Peter A and Casey, Alicia and Chang, Joyce and Henderson, Lauren A},
  title = {Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic‐Exposed Children With Systemic Juvenile Idiopathic Arthritis},
  journal = {Arthritis Care & Research},
  year = {2023},
  volume = {75},
  number = {10},
  pages = {2063--2072},
  doi = {10.1002/acr.25129}
}
Kostenlos starten →